NICE wants more Abilify data
This article was originally published in Scrip
Executive Summary
NICE, the HTA institute for England and Wales, says that it needs more information from Bristol-Myers Squibb and Otsuka Pharmaceuticals before it can assess whether or not to recommend NHS uptake of Abilify (aripiprazole) for patients aged between 15 and 17 with schizophrenia.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.